Fairvoy Private Wealth LLC Buys New Holdings in iShares Biotechnology ETF $IBB

Fairvoy Private Wealth LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,965 shares of the financial services provider’s stock, valued at approximately $1,683,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IBB. Citigroup Inc. increased its holdings in shares of iShares Biotechnology ETF by 40.9% in the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after acquiring an additional 1,521,992 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in iShares Biotechnology ETF by 313.2% during the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock worth $276,526,000 after purchasing an additional 1,451,820 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in iShares Biotechnology ETF by 286.2% in the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after purchasing an additional 736,881 shares in the last quarter. WestEnd Advisors LLC purchased a new position in iShares Biotechnology ETF in the fourth quarter valued at approximately $106,276,000. Finally, Truist Financial Corp increased its stake in iShares Biotechnology ETF by 2,239.6% in the fourth quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock valued at $108,354,000 after purchasing an additional 614,582 shares during the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of IBB opened at $183.67 on Friday. iShares Biotechnology ETF has a 1-year low of $125.70 and a 1-year high of $186.81. The firm has a fifty day moving average price of $171.22 and a 200 day moving average price of $170.92.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Monday, June 15th were issued a $0.0238 dividend. This represents a $0.10 annualized dividend and a dividend yield of 0.1%. The ex-dividend date of this dividend was Monday, June 15th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.